| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Qi Zheng, Bangshan Liu, Shuyin Xu, Mei Liao, Yan Zhang, Lingjiang L. [Research progress in mechanisms and clinical application for blonanserin and lurasidone in improving cognitive function of schizophrenia]. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences. vol 42. issue 4. 2017-12-22. PMID:28490709. |
this review introduces pathogenesis of cognitive impairment in schizophrenia, mechanisms of blonanserin and lurasidone in the improvement of cognitive impairment and progress in their clinical application for schizophrenia. |
2017-12-22 |
2023-08-13 |
Not clear |
| William M Greenberg, Leslie Citrom. Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature. Clinical pharmacokinetics. vol 56. issue 5. 2017-11-27. PMID:27722855. |
lurasidone hydrochloride, a benzisothiazol derivative, is a second-generation (atypical) antipsychotic agent that has received regulatory approval for the treatment of schizophrenia in the us, canada, the eu, switzerland, and australia, and also for bipolar depression in the us and canada. |
2017-11-27 |
2023-08-13 |
Not clear |
| Krithika Rajagopalan, David Trueman, Lydia Crowe, Daniel Squirrell, Antony Loebe. Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia. PharmacoEconomics. vol 34. issue 7. 2017-10-13. PMID:27067724. |
cost-utility analysis of lurasidone versus aripiprazole in adults with schizophrenia. |
2017-10-13 |
2023-08-13 |
Not clear |
| Krithika Rajagopalan, David Trueman, Lydia Crowe, Daniel Squirrell, Antony Loebe. Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia. PharmacoEconomics. vol 34. issue 7. 2017-10-13. PMID:27067724. |
in 2014, lurasidone, an atypical antipsychotic, was approved for the treatment of schizophrenia in adults. |
2017-10-13 |
2023-08-13 |
Not clear |
| George Awad, Daisy Ng-Mak, Krithika Rajagopalan, Jay Hsu, Andrei Pikalov, Antony Loebe. Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia. BMC psychiatry. vol 16. 2017-08-07. PMID:27245981. |
long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia. |
2017-08-07 |
2023-08-13 |
Not clear |
| George Awad, Daisy Ng-Mak, Krithika Rajagopalan, Jay Hsu, Andrei Pikalov, Antony Loebe. Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia. BMC psychiatry. vol 16. 2017-08-07. PMID:27245981. |
this analysis examines long-term changes in hrqol among patients with schizophrenia switched to lurasidone from other antipsychotics. |
2017-08-07 |
2023-08-13 |
Not clear |
| Christoph U Correll, Josephine Cucchiaro, Robert Silva, Jay Hsu, Andrei Pikalov, Antony Loebe. Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study. CNS spectrums. vol 21. issue 5. 2017-06-29. PMID:27048911. |
long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study. |
2017-06-29 |
2023-08-13 |
Not clear |
| Christoph U Correll, Josephine Cucchiaro, Robert Silva, Jay Hsu, Andrei Pikalov, Antony Loebe. Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study. CNS spectrums. vol 21. issue 5. 2017-06-29. PMID:27048911. |
to evaluate the safety and effectiveness of lurasidone in the long-term treatment of patients with schizophrenia. |
2017-06-29 |
2023-08-13 |
Not clear |
| Rafał R Jaeschke, Magdalena Sowa-Kućma, Patrycja Pańczyszyn-Trzewik, Paulina Misztak, Krzysztof Styczeń, Wojciech Datk. Lurasidone: The 2016 update on the pharmacology, efficacy and safety profile. Pharmacological reports : PR. vol 68. issue 4. 2017-06-19. PMID:27203278. |
lurasidone is an atypical antipsychotic, approved by the us food and drug administration (fda) for the treatment of schizophrenia and bipolar depression. |
2017-06-19 |
2023-08-13 |
Not clear |
| Joshua T Kantrowitz, Zafar Sharif, Alice Medalia, Richard S E Keefe, Philip Harvey, Gerard Bruder, Deanna M Barch, Tse Choo, Seonjoo Lee, Jeffrey A Lieberma. A Multicenter, Rater-Blinded, Randomized Controlled Study of Auditory Processing-Focused Cognitive Remediation Combined With Open-Label Lurasidone in Patients With Schizophrenia and Schizoaffective Disorder. The Journal of clinical psychiatry. vol 77. issue 6. 2017-06-09. PMID:27035157. |
a multicenter, rater-blinded, randomized controlled study of auditory processing-focused cognitive remediation combined with open-label lurasidone in patients with schizophrenia and schizoaffective disorder. |
2017-06-09 |
2023-08-13 |
Not clear |
| Antony Loebel, Robert Silva, Robert Goldman, Kei Watabe, Josephine Cucchiaro, Leslie Citrome, John M Kan. Lurasidone Dose Escalation in Early Nonresponding Patients With Schizophrenia: A Randomized, Placebo-Controlled Study. The Journal of clinical psychiatry. vol 77. issue 12. 2017-06-05. PMID:27454547. |
lurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized, placebo-controlled study. |
2017-06-05 |
2023-08-13 |
Not clear |
| Antony Loebel, Robert Silva, Robert Goldman, Kei Watabe, Josephine Cucchiaro, Leslie Citrome, John M Kan. Lurasidone Dose Escalation in Early Nonresponding Patients With Schizophrenia: A Randomized, Placebo-Controlled Study. The Journal of clinical psychiatry. vol 77. issue 12. 2017-06-05. PMID:27454547. |
to assess the effect of dose increase in adult patients with schizophrenia who demonstrate inadequate initial response to standard-dose lurasidone and to evaluate the efficacy of low-dose lurasidone in adult patients with schizophrenia. |
2017-06-05 |
2023-08-13 |
Not clear |
| Krithika Rajagopalan, Sally Wade, Nicole Meyer, Antony Loebe. Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis. Current medical research and opinion. vol 33. issue 5. 2017-05-26. PMID:28098496. |
real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis. |
2017-05-26 |
2023-08-13 |
Not clear |
| Krithika Rajagopalan, Sally Wade, Nicole Meyer, Antony Loebe. Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis. Current medical research and opinion. vol 33. issue 5. 2017-05-26. PMID:28098496. |
to compare adherence with lurasidone to other oral atypical antipsychotics among medicaid and commercially insured patients with schizophrenia. |
2017-05-26 |
2023-08-13 |
Not clear |
| Lurasidone for schizophrenia. Drug and therapeutics bulletin. vol 53. issue 3. 2016-10-31. PMID:25765597. |
lurasidone for schizophrenia. |
2016-10-31 |
2023-08-13 |
Not clear |
| Lurasidone for schizophrenia. Drug and therapeutics bulletin. vol 53. issue 3. 2016-10-31. PMID:25765597. |
lurasidone (latuda-sunovion) is a new oral second-generation antipsychotic licensed for treating adults with schizophrenia. |
2016-10-31 |
2023-08-13 |
Not clear |
| Fernanda S Tonin, Thais Piazza, Astrid Wiens, Fernando Fernandez-Llimos, Roberto Pontarol. Adverse events and treatment failure leading to discontinuation of recently approved antipsychotic drugs in schizophrenia: A network meta-analysis. Schizophrenia research. vol 169. issue 1-3. 2016-09-28. PMID:26516102. |
objective:we aimed to gather evidence of the discontinuation rates owing to adverse events or treatment failure for four recently approved antipsychotics (asenapine, blonanserin, iloperidone, and lurasidone).methods: a systematic review followed by pairwise meta-analysis and mixed treatment comparison meta analysis(mtc) was performed, including randomized controlled trials (rcts) that compared the use of the above-mentioned drugs versus placebo in patients with schizophrenia. |
2016-09-28 |
2023-08-13 |
human |
| Rajiv Tandon, Josephine Cucchiaro, Debra Phillips, David Hernandez, Yongcai Mao, Andrei Pikalov, Antony Loebe. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Journal of psychopharmacology (Oxford, England). vol 30. issue 1. 2016-09-26. PMID:26645209. |
a double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. |
2016-09-26 |
2023-08-13 |
Not clear |
| Rajiv Tandon, Josephine Cucchiaro, Debra Phillips, David Hernandez, Yongcai Mao, Andrei Pikalov, Antony Loebe. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Journal of psychopharmacology (Oxford, England). vol 30. issue 1. 2016-09-26. PMID:26645209. |
to evaluate the effectiveness of lurasidone as maintenance treatment for schizophrenia. |
2016-09-26 |
2023-08-13 |
Not clear |
| L Samalin, M Honciuc, P-M Llorc. [Long-term efficacy and safety of lurasidone in the treatment of schizophrenia]. L'Encephale. vol 41. issue 6. 2016-09-13. PMID:26603973. |
[long-term efficacy and safety of lurasidone in the treatment of schizophrenia]. |
2016-09-13 |
2023-08-13 |
Not clear |